Lung Cancer Treatment

A Global Strategic Business Report

MCP34035

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

7142

EXECUTIVE POOL

5850

PRICE

811

EXPERT INPUTS

34

COMPANIES

309

DATA TABLES

373

PAGES

2

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (55)

3

CXO

5

VICE PRESIDENT

10

DIRECTOR

25

MANAGER

12

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Lung Cancer Treatment Market to Reach US$79.1 Billion by 2030

The global market for Lung Cancer Treatment estimated at US$50.9 Billion in the year 2024, is expected to reach US$79.1 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. NSCLC Cancer Type, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$46.2 Billion by the end of the analysis period. Growth in the SCLC Cancer Type segment is estimated at 9.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.9 Billion While China is Forecast to Grow at 11.7% CAGR

The Lung Cancer Treatment market in the U.S. is estimated at US$13.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$16.6 Billion by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Lung Cancer Treatment Market – Key Trends & Drivers Summarized

Why Does Lung Cancer Remain a Central Focus in Global Oncology Innovation?

Lung cancer continues to represent one of the most formidable challenges in global oncology, accounting for the highest number of cancer-related deaths worldwide. Divided primarily into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), the disease is often diagnosed at advanced stages, leading to poor prognosis and high treatment urgency. The historical reliance on chemotherapy and radiation therapy is now giving way to more personalized, targeted, and immune-based approaches that are transforming treatment paradigms. Innovations in molecular diagnostics, biomarker discovery, and precision therapeutics are allowing clinicians to tailor therapies based on genetic mutations, histological subtypes, and immune profiles.

The urgency to improve survival outcomes has led to the accelerated adoption of immunotherapies, targeted kinase inhibitors, and combination regimens that deliver incremental yet meaningful gains in progression-free and overall survival. Liquid biopsy tools, next-generation sequencing (NGS), and companion diagnostics are helping oncologists match patients to the right therapy with unprecedented precision. These developments, though complex and cost-intensive, are gradually reshaping lung cancer from a uniformly grim diagnosis to a series of stratified, biomarker-defined disease states with variable treatment pathways.

How Are Targeted Therapies and Immunotherapies Reshaping Clinical Practice?

One of the most transformative changes in lung cancer treatment has been the expansion of targeted therapies for patients with actionable mutations such as EGFR, ALK, ROS1, BRAF, and MET. These therapies, including osimertinib, crizotinib, and entrectinib, block abnormal signaling pathways that drive tumor growth. Their adoption has extended survival and improved quality of life for patients who would have otherwise undergone cytotoxic chemotherapy. Moreover, resistance mutations—such as T790M in EGFR-positive tumors—are now being addressed with second- and third-generation inhibitors, reflecting the growing complexity and personalization of treatment.

Immune checkpoint inhibitors such as pembrolizumab, nivolumab, and atezolizumab have ushered in a new era in first-line and maintenance therapy, particularly for PD-L1 expressing tumors. These agents enhance the immune system`s ability to recognize and destroy cancer cells, and have become a mainstay in NSCLC treatment, either as monotherapy or in chemo-immunotherapy combinations. New indications continue to emerge for earlier-stage patients, and neoadjuvant or adjuvant immunotherapy trials are producing promising results. Biotech pipelines are also exploring novel immunomodulators such as TIGIT, LAG-3, and STING agonists to overcome immune escape and resistance mechanisms.

What Role Do Diagnostics, Screening Programs, and Regional Disparities Play in Market Dynamics?

Early diagnosis remains one of the greatest unmet needs in lung cancer management. In most regions, the majority of lung cancer cases are still detected at stage III or IV, when curative treatment is rarely possible. Low-dose CT screening programs, when implemented effectively, have been shown to reduce mortality through earlier detection. However, adoption of such programs remains uneven globally due to infrastructure constraints, cost barriers, and patient awareness gaps. The integration of AI-assisted radiology and mobile diagnostic units in underserved areas offers promise in improving early detection rates.

Companion diagnostics are becoming a linchpin in treatment selection, especially for targeted therapies and immunotherapy eligibility. NGS platforms capable of analyzing multiple mutations from a single biopsy sample are increasingly used to guide therapy decisions. Regional disparities in testing availability, however, continue to limit access to personalized care in low-resource settings. In high-income countries, the trend is toward real-time molecular tumor boards and algorithm-driven treatment decisions, while in lower-income regions, systemic challenges still restrict the reach of biomarker-driven approaches.

What Is Driving Long-Term Growth and Therapeutic Expansion in the Lung Cancer Market?

The growth in the lung cancer treatment market is driven by multiple forces including innovation pipelines, expanding patient pools, regulatory acceleration, and rising global cancer incidence. A key driver is the steady stream of new approvals for next-generation kinase inhibitors, bispecific antibodies, and ADCs (antibody-drug conjugates), which are expanding the therapeutic arsenal. Pharma companies are investing heavily in biomarker research and trial networks to capture niche subpopulations and demonstrate real-world value in head-to-head comparative studies.

Policy and reimbursement environments are evolving in favor of high-impact therapies, particularly those that offer measurable quality-of-life gains or extend survival significantly. Conditional approvals, fast-track designations, and multi-country trials are facilitating quicker market access, especially in high-burden regions. Meanwhile, patient advocacy groups and clinical networks are increasing demand for equitable access, post-treatment survivorship care, and drug affordability—broadening the scope of treatment delivery beyond just clinical efficacy.

Emerging technologies such as AI-driven drug discovery, ctDNA-based monitoring, and tumor organoids are expected to further revolutionize how lung cancer is treated and tracked. As the disease transitions from a monolithic challenge to a highly segmented therapeutic landscape, the market for lung cancer treatments is poised for sustained innovation, global expansion, and cross-disciplinary integration between diagnostics, therapeutics, and digital care platforms.

SCOPE OF STUDY

The report analyzes the Lung Cancer Treatment market by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (NSCLC Cancer Type, SCLC Cancer Type); Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy, Other Treatment Types); End-User (Hospitals End-User, Cancer & Radiation Therapy Centers End-User, Other End-Users).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..

SELECT PLAYERS

AbbVie Inc.; Amgen Inc.; Astellas Pharma Inc.; AstraZeneca plc; Bayer AG; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Daiichi Sankyo Company, Ltd.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson; Merck & Co., Inc.; Merck KGaA; Mylan N.V.; Novartis AG; Pfizer Inc.; Sanofi S.A.; Takeda Pharmaceutical Company; Teva Pharmaceutical Industries Ltd.;

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

World Market Trajectories

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Lung Cancer Treatment – Global Key Competitors Percentage Market Share in 2025 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 34 Players Worldwide in 2025 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Global Incidence of NSCLC and SCLC Drives Demand for Targeted Lung Cancer Therapies

Expansion of Immuno-Oncology Research Throws the Spotlight on Checkpoint Inhibitors and CAR-T

Rapid Advancements in Liquid Biopsy and Genomic Profiling Propel Precision Treatment Strategies

FDA Approvals of Targeted Therapies Strengthen Business Case for Personalized Oncology

Integration of AI in Oncology Diagnostics Enhances Early Detection and Drug Matching Efficiency

Increased Investment in Biologics and Monoclonal Antibodies Accelerates Treatment Pipeline Growth

Surge in Companion Diagnostics Development Expands Addressable Patient Population for Targeted Drugs

Shift Toward Combination Therapy Protocols Spurs Demand for Multimodal Lung Cancer Regimens

Growth in Biomarker-Based Clinical Trial Design Enhances Efficiency in Drug Approval Pathways

Improved Access to Molecular Testing in Emerging Markets Supports Broader Therapy Adoption

Development of EGFR, ALK, and KRAS Inhibitors Sustains Growth in Precision Drug Categories

Rise in Smoking Cessation Programs and Awareness Campaigns Drives Preventive Screening Uptake

Expansion of Outpatient Oncology Care Models Enhances Access to Maintenance Therapies

Cost Containment Policies and Tiered Pricing Accelerate Penetration of Novel Drugs in LMICs

Pharma Collaborations and Licensing Agreements Strengthen Global Launch Strategies

Growth in Inhaled Chemotherapy Delivery Systems Enhances Drug Localization and Reduces Side Effects

Real-World Data Integration Strengthens Value-Based Pricing Models in Oncology Treatment

Focus on Minimally Invasive Surgical and Radiotherapy Techniques Expands Multidisciplinary Treatment

Reimbursement Policy Reforms in High-Incidence Markets Boost Therapy Accessibility

Immunotherapy Resistance and Mutation Complexity Create Need for Second-Line Drug Innovation

4. GLOBAL MARKET PERSPECTIVE

World Lung Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Lung Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for NSCLC Cancer Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for NSCLC Cancer Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for NSCLC Cancer Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for SCLC Cancer Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for SCLC Cancer Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for SCLC Cancer Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Cancer & Radiation Therapy Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Cancer & Radiation Therapy Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Cancer & Radiation Therapy Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

JAPAN

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

CHINA

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

EUROPE

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Review for Lung Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

FRANCE

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

GERMANY

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

UNITED KINGDOM

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

SPAIN

Spain Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

RUSSIA

Russia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Lung Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

AUSTRALIA

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)

Australia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

INDIA

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)

India Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

India Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

India Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

SOUTH KOREA

South Korea Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

REST OF ASIA-PACIFIC

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

LATIN AMERICA

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)

Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Latin America Historic Review for Lung Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

ARGENTINA

Argentina Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

BRAZIL

Brazil Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

MEXICO

Mexico Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

REST OF LATIN AMERICA

Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

MIDDLE EAST

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)

Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Middle East Historic Review for Lung Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Lung Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

IRAN

Iran Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

ISRAEL

Israel Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

SAUDI ARABIA

Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

UNITED ARAB EMIRATES

UAE Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

REST OF MIDDLE EAST

Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

AFRICA

Lung Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)

Africa Recent Past, Current & Future Analysis for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Lung Cancer Treatment by Cancer Type - NSCLC Cancer Type and SCLC Cancer Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Lung Cancer Treatment by Cancer Type - Percentage Breakdown of Value Sales for NSCLC Cancer Type and SCLC Cancer Type for the Years 2015, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Lung Cancer Treatment by End-user - Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Lung Cancer Treatment by End-user - Percentage Breakdown of Value Sales for Cancer & Radiation Therapy Centers End-User, Other End-Users and Hospitals End-User for the Years 2015, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Lung Cancer Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Lung Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Other Treatment Types for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Cipla Ltd.	%
Florida Cancer Specialists	%
Myriad Genetics, Inc.	%
Pinotbio Co., Ltd.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll